Search Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologySolid TumorsProtocol groupGastroenterologic OncologySarcomasSarcomas (ped.)DiseaseLiver Sarcoma UndifferentiatedRhabdomyosarcomaSoft Tissue SarcomaSubgroupICD10C49.-MeSHRhabdomyosarcoma, EmbryonalSequencePAED Soft Tissue Sarcoma, "Non-RMS-like"-tumors (NRSTS) in the High Risk GroupPAED Soft Tissue Sarcoma, Localised "RMS-like" tumours (SySa, STET (EES, pPNET), UDS)PAED Soft Tissue Sarcoma, RMS Low Risk Group - Subgroup APAED Soft Tissue Sarcoma, RMS Standard Risk Group - Subgroup BPAED Soft Tissue Sarcoma, RMS Very High Risk Group- Subgroup HPAED Weichteilsarkom, RMS Standard Risk Group – Subgroup CPAED Weichteilsarkom, RMS Standard Risk Group – Subgroup D, E, F, GVAIA III, Soft Tissue SarcomaChemotherapyChemo-substanceDactinomycinDoxorubicinIfosfamideVincristineChemo-substanceDactinomycinDoxorubicinIfosfamideVincristineChemo-substanceDactinomycinDoxorubicinIfosfamideVincristineChemo-substanceDactinomycinDoxorubicinIfosfamideVincristineNo. Substances23 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMesnaPegfilgrastimNo. Substances458Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaNeutropeniaOral Mucositis only studiesPublicationAuthorKoscielniak E, Klingebiel TTreuner J. Koscielniak EDiseaseWeichteilsarkom, HRWeichteilsarkom, Kinder, Jugendliche und junge ErwachseneOriginCWS 2002 Protokoll der Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH)Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH), Studienprotokoll CWS-GuidanceProtocols in Revision 8 protocols foundProtocols under revision.PAED CWS-Guidance, I²VA - Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, Soft Tissue Sarcoma (PID1288 V1.0)PAED CWS-Guidance, I²VAd - Ifosfamide 3 / Vincristine 1.5 / Doxorubicin 20, Soft Tissue Sarcoma (PID1292 V1.0)PAED CWS-Guidance, VA - Vincristine 1.5 / Dactinomycin 1.5, Rhabdomyosarcoma (PID1237 V1.0)PAED CWS-Guidance, VA2 - Vincristine 1.5 / Dactinomycin 1.5, Rhabdomyosarcoma (PID1289 V1.0)VAIA III Block 1 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID657 V1.2)VAIA III Block 2 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID659 V1.3)VAIA III Block 3,4,6 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID660 V1.2)VAIA III Block 5,7,8,9 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID661 V1.3)
